General reviews
Biomarkers for prognostic assesment in malignant melanoma (Part I)
The unpredictable evolution of malignant melanoma
made necessary the finding of factors with biomarker value,
well correlated with tumor evolution process, for prognostic
assessment of the disease. In the latest decades numerous
biomarkers were considered respectively, biologically
measurable structures, on the basis of which at least two
aspects were assessed for malignant melanoma evolution:
period of time till metastases occurrence, medium life span.
In our study we aimed evaluation of these markers
starting with their level of expression : clinical level,
histological level, immunohistological level, serological
level and the genetic one.
There are presented the main biomarkers used, at present, for each level of expression, considering the correlation between these markers presence and tumor process evolution, establishing the prognostic value for each presented marker.
Our study aims to follow up the prognostic value assessment of these factors, of clinic close utility but also in the perspective of a new immunological or genetical therapies in malignant melanoma.
There are presented the main biomarkers used, at present, for each level of expression, considering the correlation between these markers presence and tumor process evolution, establishing the prognostic value for each presented marker.
Our study aims to follow up the prognostic value assessment of these factors, of clinic close utility but also in the perspective of a new immunological or genetical therapies in malignant melanoma.